A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Phase 2 clinical trial conducted in 2 parts: Part 1 - Pharmacokinetics and Part 2 -
Randomized and Placebo Controlled (subject and clinical assessors will be blinded). Study
Product will be applied to AD BID days 1-28. There will be weekly visits from Baseline (day
1) through Day 29. There is a final follow up visit 2 weeks after.